NCT04025957View on ClinicalTrials.gov

A Study of SHR-1501 in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 30, 2019

Primary Completion Date

July 31, 2022

Study Completion Date

July 31, 2022

Conditions
Advanced Malignancies
Interventions
DRUG

SHR-1501

Administered subcutaneously

Trial Locations (1)

100021

Cancer hospital, Chinese academy of medical sciences, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04025957 - A Study of SHR-1501 in Patients With Advanced Tumors | Biotech Hunter | Biotech Hunter